FDA/CDC
FDA/CDC
FDA okays first sublingual med for agitation in serious mental illness
With a demonstrated onset of action as early as 20 minutes, dexmedetomidine shows a high response rate in patients at both 120-mcg and 180-mcg...
FDA/CDC
FDA clears once-weekly transdermal patch for Alzheimer’s
Adlarity is the first and only once-weekly patch to continuously deliver consistent doses of the acetylcholinesterase inhibitor through the skin...
News from the FDA/CDC
Clozapine interrupted: APA, others seek FDA forum on REMS
Clozapine can decrease the neutrophil count, which can lead to severe neutropenia, serious infection, and death.
FDA/CDC
CDC preparing to update mask guidance
“Omicron cases are declining, and we are all cautiously optimistic about the trajectory we’re on.”
FDA/CDC
Two emerging drugs exacerbating opioid crisis
On their own, para-fluorofentanyl and metonitazene can kill the user through respiratory depression, said Dr. Jordan Trecki.
FDA/CDC
FDA grants full approval to Moderna COVID-19 vaccine
The Moderna vaccine also now has a new trade name: Spikevax.
FDA/CDC
Orally dissolving buprenorphine tied to severe tooth decay, FDA warns
Since buprenorphine was approved, the FDA has identified 305 cases of dental problems associated with orally dissolving buprenorphine.
FDA/CDC
COVID-19 linked to increased diabetes risk in youth
Two large databases indicate significantly increased diabetes risk among those with COVID-19 but not other acute respiratory illnesses.
FDA/CDC
CDC panel recommends Pfizer COVID-19 boosters for ages 12-15
CDC Director Rochelle Walensky, MD, must still approve the recommendation for it to take effect.
FDA/CDC
New CDC COVID-19 isolation guidelines still up for debate among experts
Sparking the most debate: Infected people are not told to test before leaving isolation.
FDA/CDC
FDA backs Pfizer booster for 12- to 15-year-olds
The agency also shortened the recommended time between a second dose and the booster to 5 months or more,